{
 "ticker": "PSIL",
 "name": "AdvisorShares Psychedelics ETF",
 "issuer": "AdvisorShares",
 "desk": "themes",
 "url": "https://etfiq.com/funds/PSIL",
 "html": "https://etfiq.com/funds/PSIL",
 "markdown": "https://etfiq.com/funds/PSIL.md",
 "as_of": "2026-09-11",
 "verdict": "PSIL holds 27 stocks, and 92% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "8.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PSIL, already in the S&P 500: 8.1%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "98.4%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PSIL, active share vs the S&P 500: 98.4%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "72.2%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PSIL, top ten holdings: 72.2%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+51.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PSIL, total return, 1 year: +51.5%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$44m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "PSIL, net assets: $44m (SEC filing, whole fund, as filed for Jun 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "1.00%",
   "source": "485BPOS XBRL, Oct 28, 2025",
   "as_of": "2026-09-11",
   "sentence": "PSIL, expense ratio: 1.00% (485BPOS XBRL, Oct 28, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Therapeutics and medical devices",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Sep 16, 2021",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "8.1%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "98.4%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "0.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "72.2%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "27",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Jun 30, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "DEFINIUM THERAPEUTICS INC 13.4%, COMPASS PATHWAYS PLC 11.9%, ATAIBECKLEY INC 10.9%, RELMADA THERAPEUTICS INC 7.1%, NRX PHARMACEUTICALS INC 6.3%, NEUROCRINE BIOSCIENCES INC 4.6%, CYBIN INC 4.5%, GH RESEARCH PLC 4.5%, ALKERMES PLC 4.5%, ALTO NEUROSCIENCE INC 4.4%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$44m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221272.0%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "1.00%",
   "source": "485BPOS XBRL, Oct 28, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "1.02%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "IBRN 12%, BMED 10%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+22.9%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+19.6 pts",
   "Gap to Nasdaq-100": "+23.6 pts"
  },
  {
   "window": "6 months",
   "Total return": "+49.0%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+32.9 pts",
   "Gap to Nasdaq-100": "+28.3 pts"
  },
  {
   "window": "1 year",
   "Total return": "+51.5%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+34.0 pts",
   "Gap to Nasdaq-100": "+28.5 pts"
  },
  {
   "window": "3 years",
   "Total return": "+61.5%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221216.3 pts",
   "Gap to Nasdaq-100": "\u221233.5 pts"
  },
  {
   "window": "Since launch",
   "Total return": "\u221271.2%",
   "S&P 500": "+82.9%",
   "Gap to S&P 500": "\u2212154.1 pts",
   "Gap to Nasdaq-100": "\u2212165.9 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of PSIL is in S&P 500 companies?",
   "a": "By its holdings filed for Jun 30, 2026, 8% of PSIL by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different."
  },
  {
   "q": "What does PSIL hold?",
   "a": "27 positions as filed for Jun 30, 2026, with the top ten at 72% of the fund. The largest are DEFINIUM THERAPEUTICS INC at 13.4%, COMPASS PATHWAYS PLC at 11.9%, ATAIBECKLEY INC at 10.9%."
  },
  {
   "q": "Has PSIL beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 PSIL returned +51.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 34.0 points."
  },
  {
   "q": "What does PSIL cost?",
   "a": "The prospectus expense ratio is 1.00% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 1.02%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}